Edit

Contact Us


    Human Verification

    About Us

    ABOUT US
    Everything began with a question
    "Is it possible to change the way people monitor their health?"
    CO-OP
    A Highly Specialized Molecular Testing Company based on Co-Operation
    AVAILABLE FOR EVERYONE
    Since genomic testing is expensive and risky for smaller labs,
    GTC was established as a cooperative to support smaller labs internalizing
    next-gen sequencing (NGS) with AI to help localize cancer care.
    Previous
    Next

    OUR STORY

    What Is GTC

    Genomic Testing Cooperative (GTC) is a different kind of cancer diagnostic laboratory. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. In creating a network of Co-Op partners, we help get results to physicians faster, share knowledge and generate better outcomes for patients.

    Our testing is focused on comprehensive profiling of DNA and RNA in hematologic neoplasms and solid tumors, embracing the latest sequencing technology and informatics tools; providing better insights into the patient’s tumor signature. Our RNA sequencing capabilities go beyond just the detection of fusions and include alternative splicing, gene expression and prediction. Our RNA profiling can be used to compliment flow cytometry and immunohistochemistry (IHC) testing. GTC’s capabilities include liquid biopsy testing that give physicians testing options when tissue or bone marrow isn’t available. The informatics tools we use utilize artificial intelligence with sophisticated algorithms to interpret complex data sets, these informatics tools are unmatched anywhere on the market today.

    GTC was founded in 2018 by Maher Albitar, MD who has held senior roles at numerous diagnostic laboratories and was a tenured professor at MD Anderson Cancer Center. He has committed his life to helping cancer patients by advancing cancer diagnostics and democratizing testing. Dr. Albitar founded GTC because he had a vision to revolutionize diagnostics and scientific discovery by improving access to comprehensive genomic profiling with next generation sequencing. He believes every cancer patient should have access to comprehensive genomic profiling. Dr. Albitar is regularly published in the top medical journals in oncology and has over 300 publications and authored over 50 patents.

    OUR MISSION

    We offer advanced genomic profiling for both solid and hematologic cancers to communities everywhere at an affordable price.

    GTC utilizes a cooperative business model to help physicians treat patients locally with the most advanced precision medicine made possible by advanced diagnostic information.

    We embrace disruptive technology and deep learning to create scalable efficiencies, incomparable precision, and a more personalized approach to patient care.

    OUR VISION

    We are committed to driving the field of oncology forward by enabling more patients to contribute their unique cancer experience to the growing body of cancer genomics data.

    We are committed to fulfilling precision medicine’s promise of individualized care for everyone by empowering physicians to formulate treatments that best suit each patient’s unique genetic profile.
    November, 2018
    November, 2018

    GTC opens

    Genomics Testing Cooperative is established.

    June, 2019
    June, 2019

    Medicare coverage

    GTC tests receive coverage decision from Medicare (Palmetto GBA) for all its tests including liquid biopsies
    May, 2020
    May, 2020

    GTC partners
    with JTCC

    GTC partners with John Theuer Cancer Center/RCCA to open genomics laboratory

    July, 2020
    July, 2020

    GTC partners with HMH

    GTC partners with Hackensack Meridian Health to open genomics laboratory

    March, 2021
    March, 2021

    Anthology Diagnostics opens

    Anthology Diagnostics opens in collaboration with Hackensack Meridian Health

    May, 2021
    May, 2021

    Key Genomics opens

    New lab at John Theurer Cancer Center

    June, 2021
    June, 2021

    NY State Approval

    GTC Completes NY State Approval and Medicare (Palmetto) Coverage for all DNA and RNA Tests

    May, 2022
    May, 2022

    Received CE Mark

    GTC's testing is well validated with our menu receiving numerous accreditations including Medicare approval, NY State and CE Mark.

    MEET OUR LEADING TEAM

    DECADES OF EXPERIENCE WORKING IN DIAGNOSTICS

    GTC Credentials

    MAKING GENOMICS AVAILABLE AND AFFORDABLE TO EVERYONE

    5 Reasons

    that make GTC Unique
    Monitoring Health
    Diagnosis & Classifications
    Selecting Therapy (CDX)
    Predicting Prognosis
    Monitoring Therapy
    GTC Tests

    Our Aim

    is to offer you
    Precision Medicine
    Immune Profiling
    Immunotherapy
    Genetic Predisposition
    Learn More

    HOW WE DO THAT?

    Machine / Deep Learning (AI) is the center of our analysis

    Technology Innovations

    Transforming Diagnostic Testing

    • Accurate variant calling

    • Increased efficiency

    • Easier Interpreting of NGS data

    •More accurate diagnosis, prognosis and clinical prediction

    • Treatment recommendations

    •Include new therapeutic approvals
    •Clinical trial matching

    • Large data sets for training AI

    GTC AI Neural Network.png